Companion Diagnostics in the UAE: Regulatory Guide
How MOHAP regulates companion diagnostics in the UAE, from registration and clinical validation to labelling and post-market surveillance.
How MOHAP regulates companion diagnostics in the UAE, from registration and clinical validation to labelling and post-market surveillance.
Reviewed by Mohamed Noureldin, Founder, Managing Partner & Senior Legal Consultant
Companion Diagnostics Regulation in the UAE
Related Services: Explore our healthcare legal services and medical malpractice advisory services for practical legal support in this area.
Introduction
The regulation of companion diagnostics UAE is a key part of the country's personalised medicine agenda. Companion diagnostics (CDx) are in-vitro diagnostic devices that provide essential information for the safe and effective use of a corresponding therapeutic product. They are designed to determine whether a specific treatment suits an individual patient, which makes them the linchpin of targeted therapy.
Through the Ministry of Health and Prevention (MOHAP), the UAE has established a rigorous framework to govern the approval, importation and use of these medical tools. The framework allows the healthcare sector to use the latest medical technology without compromising patient safety or data integrity.
Pharmaceutical companies, diagnostic manufacturers and healthcare providers that want to introduce or use CDx technologies in the United Arab Emirates need to understand this demanding legal landscape. Non-compliance carries substantial penalties and can block market access.
Legal Framework for Companion Diagnostics in the UAE
The UAE's regulatory environment for medical devices, including companion diagnostics UAE, is primarily governed by Federal Law No. 4 of 2015 on Medical Products, Pharmacy Profession and Pharmaceutical Establishments, and its implementing regulations. This legislation provides the legal foundation for the entire lifecycle of medical products, from development and clinical trials to registration, importation and post-market surveillance.
The law gives MOHAP authority to regulate all medical devices and in-vitro diagnostics, which explicitly includes CDx. The regulations are deliberately demanding. They create a high barrier to entry to reduce the risk of substandard or unsafe products entering the market.
Various ministerial decrees and circulars add specific guidance on the classification, registration and importation of medical devices. For instance, medical devices, including CDx, are classified according to the risk they pose to the patient and to public health, using a system harmonised with global standards.
The CDx regulations UAE are particularly stringent. They require a direct and proven link between the diagnostic test and the therapeutic product it is paired with. This calls for a coordinated submission and review process, often involving both the drug and device registration departments within MOHAP. For more information on our legal services, see our practice areas.
Ministerial Decree No. 1412 of 2017 and Risk Classification
A series of ministerial decrees adds detail on implementation. For example, Ministerial Decree No. 1412 of 2017 sets out the specific requirements for registering medical devices, including the documentation needed for the technical dossier and the process for its review.
The decree also establishes the risk-based classification system, which places devices in four classes (Class A, B, C and D) according to the potential risk they pose to patients and the public. Because of their critical role in treatment decisions, companion diagnostics are typically classified as high-risk devices (Class C or D). This subjects them to the most stringent regulatory oversight.
The classification has significant implications for the level of clinical evidence required for registration and for the extent of post-market surveillance that MOHAP mandates.
Coordinated Submission of Drug and Diagnostic Dossiers
The coordinated submission process is another critical element of the framework. It requires the dossiers for the drug and the companion diagnostic to be submitted together, so that the regulatory review of the two products runs in parallel. This allows a full assessment of the benefit-risk profile of the combined treatment.
This integrated review is a complex undertaking. It requires close collaboration between the pharmaceutical and diagnostic companies, as well as a deep understanding of the UAE's regulatory system. The process is designed to test manufacturers' claims and to ensure that only products with proven clinical value are granted market access. This rigidity protects the public and maintains the integrity of the UAE's healthcare system.
Key Requirements and Procedures
The approval process for companion diagnostics in the UAE demands a careful, well-planned approach. The procedure is designed to ensure that every CDx product meets the highest standards of safety, efficacy and quality. The following sections set out the critical requirements and steps that must be completed.
Registration and Dossier Submission
The first and most critical step is registering the companion diagnostic device with MOHAP. This involves preparing and submitting a comprehensive technical dossier.
The dossier must follow the Common Technical Document (CTD) format, an internationally agreed format for preparing well-structured applications. It must contain detailed information about the device, including its design, manufacturing process, analytical and clinical performance data, and labelling.
A key requirement is a complete risk management report, which identifies all potential risks associated with the device and sets out the measures taken to mitigate them. The submission must also include a legally binding declaration of conformity, in which the manufacturer attests that the device complies with all applicable UAE regulations. Our lawyers can guide you through this process. You can learn more about our team of lawyers.
Clinical Evidence and Validation
A cornerstone of CDx approval is robust clinical evidence that validates the analytical and clinical performance of the diagnostic test. This evidence must clearly demonstrate the link between the CDx and the corresponding therapeutic product.
The clinical validation data must prove that using the CDx leads to improved clinical outcomes, such as increased efficacy or reduced toxicity of the drug. The data must come from well-designed, controlled clinical trials conducted in accordance with international ethical and scientific standards. The evidence must also be specific to the intended use of the CDx and the target patient population.
This requirement places a significant burden of proof on the manufacturer, who must design a clinical development programme that can withstand rigorous scrutiny by the regulatory authorities.
Labelling and Instructions for Use
The labelling and instructions for use (IFU) of a companion diagnostic are critical parts of the regulatory submission and are closely scrutinised. The labelling must be clear and concise and provide all the information needed for the safe and effective use of the device. This includes the intended use, the target population, the specific drug it accompanies, and any limitations or warnings.
The IFU must give detailed, step-by-step instructions on how to perform the test, interpret the results and troubleshoot potential issues. All labelling and IFU must be provided in both Arabic and English, and must be written in language that the intended user, who may be a laboratory technician or a physician, can easily understand. For any legal inquiries, please contact us.
| Document Type | Description | Key Considerations |
|---|---|---|
| Technical Dossier | Comprehensive file on the CDx device, including design, manufacturing and performance data. | Must follow the CTD format; includes the risk management report and declaration of conformity. |
| Clinical Validation Study | Report on the clinical trials that prove the CDx's efficacy and its link to the therapeutic product. | Must come from well-controlled trials; demonstrates improved clinical outcomes. |
| Labelling and IFU | All text and instructions accompanying the device. | Must be in Arabic and English; clear, concise and user-friendly. |
| Legalised Documents | Official documents from the country of origin, such as a Certificate of Free Sale. | Must be authenticated by the UAE embassy in the country of origin. |
Post-Market Surveillance and Vigilance
Regulatory obligations for companion diagnostics do not end with market approval. The UAE has a robust post-market surveillance and vigilance system to monitor the safety and performance of medical devices once they are in use.
CDx manufacturers are required to have a comprehensive post-market surveillance plan that actively collects and analyses data on the device's performance. This includes monitoring for adverse events, product complaints and performance issues. The manufacturer is legally obliged to report any serious adverse events to MOHAP within a specified timeframe. This reporting system, known as the National Vigilance System for Medical Devices, is a critical part of the UAE's efforts to reduce potential risks to public health.
In addition to reactive reporting, manufacturers are also required to produce periodic safety update reports (PSURs), which assess the device's safety profile at regular intervals. This proactive approach ensures that emerging safety signals are identified and addressed promptly.
The system places a continuous burden on the manufacturer to demonstrate the ongoing safety and effectiveness of its product. Failure to comply with post-market obligations can result in severe penalties, including suspension or withdrawal of the product's registration. The framework is designed to ensure that the benefits of companion diagnostics continue to outweigh their risks throughout the product lifecycle.
Strategic Implications of CDx Regulations in the UAE
The stringent regulatory framework for companion diagnostics UAE has significant strategic implications for everyone in the healthcare sector.
For pharmaceutical companies, co-developing a drug and its companion diagnostic is no longer a choice but a necessity for many targeted therapies. This requires a fundamental change in drug development, with the diagnostic and therapeutic developed together from the earliest stages of research. This integrated approach is resource-intensive, but it can ultimately reduce risk in drug development and increase the likelihood of regulatory success.
For diagnostic manufacturers, the UAE market offers a significant opportunity, but one protected by a high barrier to entry. Success requires a deep understanding of the CDx regulations UAE and a commitment to generating the high-quality clinical evidence that MOHAP demands.
Healthcare providers, in turn, must invest in the infrastructure and training needed to use these advanced diagnostic tools effectively. Integrating companion diagnostics into clinical practice requires a multidisciplinary approach involving oncologists, pathologists and laboratory scientists. The changes required to accommodate this technology will ultimately lead to a more personalised and effective healthcare system. Our legal insights blog covers the latest legal developments in the UAE.
Conclusion
The UAE has built a demanding and well-structured regulatory framework for companion diagnostics, reflecting its commitment to adopting advanced medical technologies while prioritising patient safety. The legal and procedural requirements are intentionally strict. They are designed to reduce the risks associated with these complex devices and to ensure that only the most rigorously validated products reach the market.
Meeting these requirements calls for a proactive and informed strategy, a deep understanding of the CDx regulations UAE, and a commitment to generating robust clinical evidence. The path to market access is challenging, but for those who can meet the high standards set by the UAE authorities, the rewards are substantial.
As personalised medicine continues to evolve, the role of companion diagnostics UAE will only grow in importance. A thorough understanding of the governing legal framework is an indispensable asset for everyone in the healthcare sector. For more information about our firm, please visit our about us page.
Additional Resources
Explore more of our insights on related topics: